Processa Pharmaceuticals, Inc. — Net Income by Fiscal Year
14 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/698681b6-c8a8-4cf6-bf45-df05a48f3cb1/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $13.6M | 2025-01-01 – 2025-12-31 | evidence 0001493152-26-029326 |
| FY 2024 | $-11.8M | 2024-01-01 – 2024-12-31 | evidence 0001493152-26-029326 |
| FY 2023 | $-11.1M | 2023-01-01 – 2023-12-31 | evidence 0001493152-26-029326 |
| FY 2022 | $-27.4M | 2022-01-01 – 2022-12-31 | evidence 0001493152-23-009730 |
| FY 2021 | $-11.4M | 2021-01-01 – 2021-12-31 | evidence 0001493152-22-008156 |
| FY 2020 | $-14.4M | 2020-01-01 – 2020-12-31 | evidence 0001493152-21-006807 |
| FY 2019 | $-3.4M | 2019-01-01 – 2019-12-31 | evidence 0001493152-20-003534 |
| FY 2018 | $-3.8M | 2018-01-01 – 2018-12-31 | evidence 0001493152-19-004137 |
| FY 2017 | $-1.9M | 2017-01-01 – 2017-12-31 | evidence 0001493152-18-005248 |
| FY 2016 | $-1.9M | 2016-01-01 – 2016-12-31 | evidence 0001493152-18-005248 |
| FY 2015 | $-3.4M | 2015-01-01 – 2015-12-31 | evidence 0001393905-17-000190 |
| FY 2014 | $-4.5M | 2014-01-01 – 2014-12-31 | evidence 0001393905-15-000193 |
| FY 2013 | $-7.8M | 2011-03-29 – 2014-03-31 | evidence 0001393905-14-000288 |
| FY 2012 | $-2.4M | 2012-01-01 – 2012-12-31 | evidence 0001393905-14-000131 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Processa Pharmaceuticals, Inc. — all facts · Revenue · Operating Income